Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction (EMPEROR-Reduced) was designed to be more ambitious than DAPA-HF, recruiting a HF population that had on average more severe systolic dysfunction (mean EF 27% vs. 31%; N-terminal pro B-type natriuretic peptide (NT-proBNP) 1907 vs. 1437) [32]. Here, NPPB is linked to hydrops fetalis.